Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 409 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Scientists developing urine and blood tests to detect brain tumours July 23, 2021 Zucchini everywhere October 9, 2020 Two Years After Cancer Diagnosis, Swimmer Rikako Ikee Has Qualified For... April 7, 2021 Regional Node Radiotherapy Significantly Reduced Breast Cancer Mortality and All-Cause Mortality... November 10, 2023 Load more HOT NEWS FDA Approves Zanubrutinib for Waldenström’s Macroglobulinemia Biomedical Engineering Student Invents Device for At-Home Breast Cancer Screening FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for Non-Small Cell Lung... Topotecan–Berzosertib Combination Shows Promise against Small Cell Lung Cancer
